- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00671151
Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
May 2, 2008 updated by: Hospital Universitari Son Dureta
Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline
Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project.
NF-kappa B-dependent pathway and acetylation status of nuclear histones are to be studied.Design: controlled, prospective and randomized study with or without theophylline, a potent HDAC activator.Objectives: 1) To determine NF-kB activation, histone deacetylase (HDAC) and histone acetyl-transferase (HAT) activity in sputum macrophages and blood monocytes during an episode of exacerbation and 3 months later, once stability is achieved.
To correlate these measurements with inflammatory and oxidative stress markers and with pulmonary function and clinical variables.
2) To assess the effect of theophylline on previous molecular, functional and clinical data.
Method: 25 patients with COPD will be recruited during an episode of exacerbation requiring hospitalization.
NF-kB activation, HDAC and HAT activity, markers of inflammation and oxidative stress will be determined with specific assays.
These determinations will be repeated once the patient is stable and compared with smokers and non smoker controls with normal lung function
Study Overview
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Baleares
-
Palma de Mallorca, Baleares, Spain, 07014
- Hospital Universitario Son Dureta
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Severe COPD according to GOLD guidelines
- Age between 40 and 75
- Admission to hospital due to COPD exacerbation
Exclusion Criteria:
- History of asthma
- Pulmonary embolism
- Pneumonia
- Other chronic inflammatory disease
- Patient on theophylline at the time of admission
- Patient on oral steroids at the time of admission
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Low-dose theophylline on top of standard therapy for COPD exacerbation
|
Theophylline 100 mg bid for 3 months
|
No Intervention: 2
Standard therapy for COPD exacerbation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HDAC activity in alveolar macrophages
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lung function
Time Frame: 3 months
|
3 months
|
Inflammatory cytokine release in sputum and serum
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Borja G Cosio, MD, Hospital Universitario Son Dureta
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004 Sep 6;200(5):689-95. doi: 10.1084/jem.20040416. Epub 2004 Aug 30.
- Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax. 2009 May;64(5):424-9. doi: 10.1136/thx.2008.103432. Epub 2009 Jan 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2005
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
April 30, 2008
First Submitted That Met QC Criteria
May 2, 2008
First Posted (Estimate)
May 5, 2008
Study Record Updates
Last Update Posted (Estimate)
May 5, 2008
Last Update Submitted That Met QC Criteria
May 2, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Theophylline
Other Study ID Numbers
- FIS042146
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Not yet recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
University Hospital, BrestRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Baylor Research InstituteNot yet recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
Clinical Trials on Theophylline
-
Ashley ShoemakerEnrolling by invitationPseudohypoparathyroidism Type 1a | Albright Hereditary Osteodystrophy | PseudohypoparathyroidismUnited States
-
The First Affiliated Hospital of Guangzhou Medical...Completed
-
Medical College of WisconsinUniversity of OklahomaRecruitingAcute Kidney Injury | HIEUnited States
-
Washington University School of MedicineCompletedCovid19 | Anosmia | SARS-CoV-2 Infection | Olfactory Disorder | Ageusia | Covid-19 Pandemic | Hyposmia | HypogeusiaUnited States
-
University of MiamiNational Heart, Lung, and Blood Institute (NHLBI)CompletedCOPD | COPD Exacerbation | Pollution; Exposure | COPD Exacerbation Acute | Pollution Related Respiratory DisorderUganda
-
Zhujiang HospitalCompletedChronic Obstructive Pulmonary Disease | AsthmaChina
-
Boehringer IngelheimCompleted
-
Technical University of MunichCompletedRadiographic Contrast Agent Nephropathy
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); North Central Cancer Treatment GroupCompletedLeukemiaUnited States, South Africa, Puerto Rico
-
The George InstituteNational Health and Medical Research Council, AustraliaCompletedChronic Obstructive Pulmonary DiseaseAustralia